Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 5

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
     -  
     (44) 
     -  
     (44)
  
    Net loss 
     -  
     -  
     -  
     -  
     (9,746) 
     (9,746)
  
    Balance as of June 30, 2024 
     19,706,732  
    $20  
    $178,767  
    $(713) 
    $(141,793) 
    $36,281 
  
    Stock-based compensation 
     -  
     -  
     1,719  
     -  
     -  
     1,719 
  
    Common stock and warrants issued for cash 
     2,390,022  
     2  
     12,290  
     -  
     -  
     12,292 
  
    Reclassification from redeemable common stock 
     75,697  
     -  
     799  
     -  
     -  
     799 
  
    Loss on foreign currency translation 
     -  
     -  
     -  
     (323) 
     -  
     (323)
  
    Net loss 
     -  
     -  
     -  
     -  
     (12,093) 
     (12,093)
  
    Balance as of September 30, 2024 
     22,172,451  
     22  
     193,575  
     (1,036) 
     (153,886) 
     38,675 

The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.

4

INMUNE BIO INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

    For the Nine Months Ended  September 30, 

    2025  
    2024 
  
    CASH FLOWS FROM OPERATING ACTIVITIES: 

    Net loss 
    $(40,669) 
    $(32,864)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Stock-based compensation 
     6,594